veralipride

Veralipride is a small molecule, atypical antipsychotic of the benzamide class. It acts as a selective dopamine D2 receptor antagonist, leading to increased prolactin secretion without estrogenic or progestagenic effects. Veralipride was primarily indicated for the treatment of vasomotor symptoms associated with menopause (such as hot flushes), especially when hormone therapy was contraindicated or not accepted. It has also been used in the management of psychosis. The drug is well absorbed orally, has a half-life of about 4 hours, and is eliminated via urine and feces with minimal metabolism. Notably, it can cause hyperprolactinemia and extrapyramidal side effects such as dyskinesia and Parkinsonism; serious psychiatric adverse events have also been reported. Veralipride was first approved in 1979 but has since been withdrawn from most markets due to safety concerns[1][3][4][5].

Brand names

AgrealAgradil

Other names

veralipridaveralipridum